Aminoglycoside monitoring: use of a pharmacokinetic service versus physician recommendations.

M. Smith, John E Murphy, M. L. Job, E. S. Ward

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Two patient populations were evaluated regarding the monitoring of aminoglycoside serum concentrations by either a pharmacokinetic service (PKS) or staff physicians. Both groups were evenly matched by demographic characteristics, underlying disease state(s), and indication for aminoglycoside therapy. Patients in the PKS group showed increased incidence of clinical improvement after therapy when compared with the physicians' group; a decreased length of stay and duration of treatment were also observed in this group. Aminoglycoside dosing and monitoring by the PKS provided an estimated average cost savings of $491,00 per patient. The results indicate that the PKS may provide cost savings and benefit in aminoglycoside monitoring for the patient and/or the hospital.

Original languageEnglish (US)
Pages (from-to)92-99, 102
JournalHospital Formulary
Volume22
Issue number1
StatePublished - Jan 1987
Externally publishedYes

Fingerprint

Aminoglycosides
Pharmacokinetics
Physicians
Cost Savings
Physiologic Monitoring
Cost-Benefit Analysis
Length of Stay
Therapeutics
Demography
Incidence
Serum
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aminoglycoside monitoring : use of a pharmacokinetic service versus physician recommendations. / Smith, M.; Murphy, John E; Job, M. L.; Ward, E. S.

In: Hospital Formulary, Vol. 22, No. 1, 01.1987, p. 92-99, 102.

Research output: Contribution to journalArticle

@article{7abbb8f01af3473fa3140b029f497668,
title = "Aminoglycoside monitoring: use of a pharmacokinetic service versus physician recommendations.",
abstract = "Two patient populations were evaluated regarding the monitoring of aminoglycoside serum concentrations by either a pharmacokinetic service (PKS) or staff physicians. Both groups were evenly matched by demographic characteristics, underlying disease state(s), and indication for aminoglycoside therapy. Patients in the PKS group showed increased incidence of clinical improvement after therapy when compared with the physicians' group; a decreased length of stay and duration of treatment were also observed in this group. Aminoglycoside dosing and monitoring by the PKS provided an estimated average cost savings of $491,00 per patient. The results indicate that the PKS may provide cost savings and benefit in aminoglycoside monitoring for the patient and/or the hospital.",
author = "M. Smith and Murphy, {John E} and Job, {M. L.} and Ward, {E. S.}",
year = "1987",
month = "1",
language = "English (US)",
volume = "22",
pages = "92--99, 102",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "1",

}

TY - JOUR

T1 - Aminoglycoside monitoring

T2 - use of a pharmacokinetic service versus physician recommendations.

AU - Smith, M.

AU - Murphy, John E

AU - Job, M. L.

AU - Ward, E. S.

PY - 1987/1

Y1 - 1987/1

N2 - Two patient populations were evaluated regarding the monitoring of aminoglycoside serum concentrations by either a pharmacokinetic service (PKS) or staff physicians. Both groups were evenly matched by demographic characteristics, underlying disease state(s), and indication for aminoglycoside therapy. Patients in the PKS group showed increased incidence of clinical improvement after therapy when compared with the physicians' group; a decreased length of stay and duration of treatment were also observed in this group. Aminoglycoside dosing and monitoring by the PKS provided an estimated average cost savings of $491,00 per patient. The results indicate that the PKS may provide cost savings and benefit in aminoglycoside monitoring for the patient and/or the hospital.

AB - Two patient populations were evaluated regarding the monitoring of aminoglycoside serum concentrations by either a pharmacokinetic service (PKS) or staff physicians. Both groups were evenly matched by demographic characteristics, underlying disease state(s), and indication for aminoglycoside therapy. Patients in the PKS group showed increased incidence of clinical improvement after therapy when compared with the physicians' group; a decreased length of stay and duration of treatment were also observed in this group. Aminoglycoside dosing and monitoring by the PKS provided an estimated average cost savings of $491,00 per patient. The results indicate that the PKS may provide cost savings and benefit in aminoglycoside monitoring for the patient and/or the hospital.

UR - http://www.scopus.com/inward/record.url?scp=0023211683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023211683&partnerID=8YFLogxK

M3 - Article

C2 - 10280287

AN - SCOPUS:0023211683

VL - 22

SP - 92-99, 102

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 1

ER -